Novo Nordisk's Wegovy Pill: FDA Approval, Efficacy, and Rapid Primary Care Adoption

In a critical expansion of the oral obesity market, the U.S. FDA approved Novo Nordisk’s once-daily Wegovy® pill (semaglutide tablets, 25 mg) on December 22, 2025, with the commercial launch taking place in early January 2026. This represents the first oral GLP-1 approved for chronic weight management in the United States.

Clinical Efficacy (OASIS 4 Trial)

The FDA approval was supported by the OASIS 4 Phase 3 clinical trial, which evaluated 307 adults with obesity or overweight and comorbidities, without diabetes, over a 64-week period:

• Completer Analysis: Participants who remained fully compliant on once-daily Wegovy pill 25 mg achieved an average weight loss of 16.6% (approx. 17%), compared to 2.7% (approx. 3%) for placebo.
• Intention-to-Treat (ITT) Analysis: Regardless of treatment adherence, participants taking the Wegovy pill achieved an average weight loss of 13.6% (approx. 14%), compared to 2.4% (approx. 2%) for placebo.
• Cardiovascular Benefit: Like its injectable counterpart, the Wegovy pill is indicated to reduce the risk of major adverse cardiovascular events (MACE), including stroke, heart attack, and cardiovascular death, in adults with overweight or obesity and established cardiovascular disease.

Rapid Physician Adoption and Market Expansion

Early market data from Spherix Global Insights' Launch Dynamix™ series (released February 20, 2026) reveals that the oral formulation is experiencing exceptional uptake:

• Prescribing Rates: Within its first month post-launch, 73% of primary care physicians (PCPs) and 78% of endocrinologists surveyed reported already prescribing the Wegovy pill.
• Market Expansion vs. Cannibalization: Rather than simply cannibalizing existing injectable GLP-1 therapies (such as injectable Wegovy or Lilly’s Zepbound), the Wegovy pill is acting as a major market expander. Physicians report that the oral option is successfully capturing patient segments who previously deferred treatment due to a fear of self-injection.
• Awareness: Unaided awareness of the Wegovy pill among surveyed PCPs leaped from 14% in November 2025 (pre-approval) to 60% in February 2026, and from 11% to 78% among endocrinologists.

Dosing and Pricing Dynamics

• Strict Fasting Requirements: A key competitive hurdle for the Wegovy pill is its administration protocol. Because it is a peptide, oral semaglutide requires strict fasting: patients must take it on an empty stomach with a small sip of water and wait at least 30 minutes before eating, drinking, or taking other oral medications.
• Launch Pricing: The starting dose (1.5 mg) launched at $149 per month with manufacturer savings offers, with robust supply manufactured directly in Novo Nordisk's North Carolina facilities.